Scholarlink

<p>Telogen effluvium (TE), a form of non-scarring hair loss, has been increasingly reported following COVID-19 infection. This study sought to investigate the relationship between COVID-19 severity and TE development. We performed a single-institution retrospective analysis of health records from patients who were diagnosed with COVID-19 between January 2020–June 2022 with ≥ 1 dermatology visit within 180&#xa0;days post-infection. Treatment setting was used as a proxy for COVID-19 infection severity (outpatient vs. emergency/inpatient). The association between severity and TE development was evaluated with multivariate logistic regression. Time-to-TE diagnosis was also compared using Kaplan–Meier analysis. Among 10,861 patients, 168 were diagnosed with TE. Patients who received emergency/inpatient care for COVID-19 were more likely to develop TE compared to those managed as outpatients (3.0% vs. 1.4%, p &lt; 0.001) and exhibited higher odds of TE on multivariate analysis (aOR: 2.56; 95% CI: 1.72–3.72, p &lt; 0.001). TE is a potential sequela of COVID-19 infection, particularly among patients who initially present with more severe COVID-19 infection. Clinicians should monitor and counsel patients on TE following COVID-19 infection, particularly those who were hospitalized for COVID-19.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Greater susceptibility to telogen effluvium in the setting of severe COVID-19 infection: findings from a retrospective cohort study

  • 期刊论文

  • 发表日期：

    2026年1月10日

查看全文
  • Shiv Patel,
  • Maria Colavincenzo

摘要

Telogen effluvium (TE), a form of non-scarring hair loss, has been increasingly reported following COVID-19 infection. This study sought to investigate the relationship between COVID-19 severity and TE development. We performed a single-institution retrospective analysis of health records from patients who were diagnosed with COVID-19 between January 2020–June 2022 with ≥ 1 dermatology visit within 180 days post-infection. Treatment setting was used as a proxy for COVID-19 infection severity (outpatient vs. emergency/inpatient). The association between severity and TE development was evaluated with multivariate logistic regression. Time-to-TE diagnosis was also compared using Kaplan–Meier analysis. Among 10,861 patients, 168 were diagnosed with TE. Patients who received emergency/inpatient care for COVID-19 were more likely to develop TE compared to those managed as outpatients (3.0% vs. 1.4%, p < 0.001) and exhibited higher odds of TE on multivariate analysis (aOR: 2.56; 95% CI: 1.72–3.72, p < 0.001). TE is a potential sequela of COVID-19 infection, particularly among patients who initially present with more severe COVID-19 infection. Clinicians should monitor and counsel patients on TE following COVID-19 infection, particularly those who were hospitalized for COVID-19.